Daré Bioscience (NASDAQ:DARE – Get Free Report) issued its earnings results on Monday. The biotechnology company reported ($0.64) EPS for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02, Zacks reports.
Daré Bioscience Price Performance
Daré Bioscience stock traded up $0.01 during trading hours on Monday, reaching $2.89. The stock had a trading volume of 30,644 shares, compared to its average volume of 45,577. The stock has a market cap of $25.14 million, a PE ratio of -4.89 and a beta of 1.38. The company has a fifty day simple moving average of $3.07 and a 200-day simple moving average of $3.29. Daré Bioscience has a 52 week low of $2.67 and a 52 week high of $7.56.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and issued a $12.00 price objective on shares of Daré Bioscience in a report on Tuesday, December 17th.
About Daré Bioscience
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Articles
- Five stocks we like better than Daré Bioscience
- What Does Downgrade Mean in Investing?
- 3 Buyable Stocks With Solid Bottoms Ready to Rebound
- Manufacturing Stocks Investing
- Advantage+ Shopping: Meta’s Fast Growing $20 Billion AI-Ads Star
- Investing in the High PE Growth Stocks
- Robotaxi News: What Tesla and Lyft Headlines Mean for Shares
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
